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                                    ABSTRACT 
 
 
The misfolding and aggregation of proteins into amyloids has been linked to a large group of 
variety amyloid-related diseases. This group consists of variety human diseases such as 
Alzheimers disease, Parkinson’s disease, Hungtington’s disease, atherosclerosis etc. 
Aggregation of proteins, such as aβ in Alzheimer’s disease, appears to lead to the formation 
of toxic assemblies. These assemblies can be very small in size like oligomers(consisting of 
very few proteins) and can reach a maximum of thousands of proteins which leads to fibril 
formation. It has been found out that inhibiting the aggregation of these proteins could slow 
down the process of formation of these neurodegerative diseases. But still there is truancy of 
a possible therapy that could effectively prevent the formation of amyloid fibrils. Thus in 
present study we try to understand the mechanism by which the small compounds which we 
have selected inhibits the target protein or the amyloid beta peptide. Here we understand the 
type of interaction and whether the compounds binds near the amyloidogenic region. We 
have also tried to understand the binding between two amyloid protein. Here we have 
choosen an amyloidogenic protein beta amyloid (1-42), pdbid-1IYT, that is processed from 
the amyloid precursor protein(APP). While best known as the component of amyloid plaques 
in association with Alzheimer’s disease, as A-beta is the main component of certain deposits 
found in the brain of patients with Alzheimer’s disease. The small compounds selected here 
are mostly cholesterol reducing agents such as statins, wine related compounds, green tea 
related components, polyphenols, phenothiazines. These compounds are found to inhibit 
amyloid fibrillogenesis in vivo. So here we adduce a mechanism by which these small 
compounds inhibit the aggregation of amyloid beta(1-42)peptide. 
 
 
KEYWORDS: Alzheimers disease, neurodegerative diseases, amyloid beta peptide, 
amyloidogenic region, amyloid precursor protein, amyloid fibrillogenesis. 
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                                 INTRODUCTION 
 
In the last few decades, scientists have made substantial progress in the discovery of new 
medicines. These advances in medicine and technology are making our lives longer. Sadly as 
our life expectancy increases, the chances of getting a degenerative disease like Alzheimer’s 
disease increase. The diseases are not caused by bacteria or virus but something which very 
elementary i.e. incorrect protein folding. Many proteins associated with many age-related 
diseases have dissimilar sequence, structure and function, but they can all form similar highly 
ordered amyloid fibrils. They have many common properties like, possession of cross beta 
structure, double refracts upon staining with dyes like congo red, protease resistance and 
insolubility in most solvents and also has a fibrillar morphology. Amyloid beta peptide 
accumulation within the brain is a hallmark of Alzheimer’s disease pathology. Accumulation 
of aggregated abeta is hypothesized to initiate a pathological cascade that results in cognitive 
decline. Abeta species are generated from the amyloid beta protein precursor (APP) through 
cleavage by beta and gamma secretases. A 40 amino acid form of abeta (aβ 40) is the major 
secreted product of these proteolysis activity , but the minor 42-amino acid form of abeta 
(aβ42) has been found out to be the main initiating molecule in the pathogenesis of 
Alzheimer’s disease. Aβ 42 aggregates very fast as compared to aβ 40. This type of 
aggregation leads to a large number of diseases such as Alzheimer’s disease, Parkinson’s 
disease, prion disease, and type 2 diabetes. No real cure is currently available towards 
treating the disease, the attenuation of amyloid fibrillation and capture of fibrillar species 
have been so far considered an effective approach. One approach is the use of small 
compounds that can inhibit the aggregation process. Several small compounds from various 
groups have been found out to inhibit the fibrillar assemblies in vivo and their associated 
cytotoxicity. By various observations related to this we can propose an effective mechanism 
about the interaction of such compounds with the peptide. This study of the mechanism may 
be highly essential for the treatment of amyloid related diseases. 
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY 
Identification of the location of ligand binding sites on a protein is of fundamental importance 
for a range of applications including molecular docking, de-novo drug designing and 
structural identification and also helps in comparison of functional sites. Now-a-days  the 
enhancement of bioinformatics and cheminformatics is paving the way for easy study of 
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protein-ligand interaction. Computational biology and bioinformatics have the potential to 
speed up this process and also it helps in reducing the cost. Docking is method which predicts 
the preferred orientation of one molecule to another molecule when they are bound together 
to form a stable complex molecule. Here two molecule bind to each other in a three-
dimensional space. Docking can be referred to as “lock and key” model. Here the protein can 
be a lock and the ligand can be called as key. There are various tools used for docking studies 
with the help of bioinformatics. Using the bioinformatics tools time and cost of biological 
work reduces drastically.  
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                           LITERATURE REVIEW 
PROTEINS 
Proteins are biochemical compounds consisting of one or more polypeptides. These are 
generally folded into a globular or fibrous form which allows for a biological function. A 
polypeptide is a single linear polymer chain of amino acids. They bonding between them is 
made by the peptide bonds between the carboxyl and amino groups of adjacent amino acid 
residues. Proteins work together to achieve a particular function and they often associate to 
form stable protein complexes. Biochemistry is the science that studies the chemical 
processes in living organisms. Using different experimental models, biochemists 
demonstrated that most of the cell’s chemical reaction and structural components are 
mediated or supplied by proteins. They concluded that proteins are very important for proper 
cell functioning. Each protein within the body has its special work. Some proteins are 
involved in structural support while others are involved in bodily movement. Some are also 
involved in defence against germs. The word protein comes from the greek word ‘proteios’ 
meaning ‘first’ or ‘foremost’ which itself indicates its importance. The proteins are basically 
long polymers which are made up of small units called amino acids.[1] 
PROTEIN FOLDING 
One important example of biological self assembly is folding of protein into its compact three 
dimensional structure. Understanding of this complex process is very important. Folding of 
protein is related to many biological processes such as molecular trafficking to particular 
cellular locations and regulation of cellular growth and differentiation. Failure of proteins to 
fold correctly is cause for a variety of diseases [1]. Almost half a century ago, Linus Pauling 
discovered two quite simple regular arrangements of amino acids, the alpha-helix and beta- 
sheet protein. In 1960’s, Christian Anfinsen discovered that proteins actually tie themselves. 
He said that if proteins become unfolded, they immediately fold back to proper shape of their 
own and hence no shaper or folder is required [3]. Native states of proteins always 
correspond to structures that are most thermodynamically stable [4]. The change in 
conformation between the unfolded and incompletely folded polypeptide chain enable the 
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residues to come close to one another. The interactions in the native state are more stable than 
the non-native ones. Hence the native polypeptide chains find its lowest energy structure. 
(figure.1) shows the energy landscape. It shows the transition from a random coil to a native 
structure [4-5]. This is based on ideas of statistical mechanics and polymer physics than on 
those of classical dynamics. This is often referred as ‘new view’ of protein folding [6]. 
Folding in vitro of some of the proteins is in fact very easily achieved. Alpha-helices are able 
to form in less than 100ns, and beta-turns are able to form within 1 micro seconds. Folding of 
helical bundles is completed in less than 10 micro seconds. But beta –sheets can take longer 
time to fold [7]. The mechanism of protein folding involves the interaction of small number 
of residues to form a folding nucleus, about which the remainder of the structure rapidly 
condenses [8]. Fundamental mechanism of protein folding involves the interaction of small 
number of residues to form a folding nucleus. The figure (1) suggests that correct folding into 
minimum energy of the protein is finally achieved due to some properties. To reach the native 
point it has to cross a barrier which corresponds to the transition phase. The folding of 
proteins is achieved due to interaction between the amino acids. It follows a funnel like 
energy landscape which speeds up the folding process [3]. 
 
Figure 1: The energetic funnel. 
(Source:Dobson , C.M. Protein Folding and Misfolding, Nature 426, 884-890(2003) ) 
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PROTEIN AGGREGATION  
For many years scientists have been investigating on the causes of many types of diseases. 
They found out that many proteins associated with such diseases form similar highly ordered 
amyloid fibrils [2]. Amyloidoses is the condition when soluble proteins become insoluble and 
are deposited in tissues and organs and disrupting the normal function. The general cause for 
formation of amyloid aggregates is the special properties of the polypeptide chains. 
Aggregates of proteins not associated with disease can impair the ability of cells to function 
to a similar extent. It has also been found out that the mature amyloid fibrils are less toxic 
than the pre fibrillar aggregates. These pre fibrillar aggregates interacts with cellular 
membranes, causing oxidative stress and increase in free Ca
2+
 that leads to cell death. Use of 
chaperons can be very helpful in preventing such diseases [9]. The charge of molecule, 
secondary-structure and number of hydrophobic side surfaces influence the aggregation rates 
for a wide range of proteins [10]. The hydrophobic side chain and main polypeptide chain 
buries into the core region when proper folding occurs. After misfolding of the nascent 
protein it results in degradation or aggregation. The cellular environment, molecular 
chaperons are very vital for the transition between the different states of protein whose failure 
may cause misfolding diseases [11]. 
Table (1) shows a list of amyloidogenic diseases. 
(Source: http://en.wikipedia.org/) 
Disease Protein featured abbreviation 
Alzheimer’s disease Beta- amyloid aβ 
Diabetes mellitus type 2 IAPP(amylin) AIAPP 
Parkinson’s disease Alpha - synnuclein none 
Huntington’s disease huntingtin none 
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Medullary carcinoma of the 
thyroid 
calcitonin ACal 
Cardiac arrhythmias, isolated 
atrial amyloidosis 
Atrial matriuretic factor AANF 
Atherosclerosis Apolipoprotein AI AApoA1 
Rheumatoid arthritis Serum amyloid A AA 
Prolactinomas Prolactin  APro 
  
ABETA AMYLOIDOGENESIS 
Deposits of large amount of single, insoluble proteins around the degenerating nerve cells 
gradually lead to Alzheimer’s disease. Alzheimer’s disease affects people over 65 years of 
age. Every year Alzheimer’s disease not only kills 10,000 Americans but also costs billions 
for the cure of them. Brain regions involved in learning and memory process, including 
temporal and frontal lobe are reduced in size in AD patients. This is the result of death of 
neurons. In AD it has been found out that the brain of the patients contains “plaques and 
tangles”. Plaques are insoluble deposits of fibrils and aggregates of amyloid beta peptide. 
Neurofibrillary tangles are fibrillar aggregates of the microtubule associated protein tau that 
exhibits hyperphosphorylation and oxidative modifications [12]. APP also known as amyloid 
precursor protein is the brain protein. It is produced in several different isoforms. The most 
abundant form in brain (APP695) is produced mainly by neurons. Cleavage of APP by the α– 
secretase releases a secreted APP (alpha) and leaves an 83-amino acid carboxy terminal APP 
fragment (c83). [12]. The APP is cleaved by two enzymes; β – secretase and forms aβ 
peptide. Another enzyme is γ secretase and forms aβ peptide and it aggregates in brain. The 
aβ amyloids are short sticky fragments [13].  
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Figure 3: formation of amyloid beta peptide from APP. 
(Source: http://en.wikipedia.org/) 
 
 
INHIBITION OF AMYLOID BETA PEPTIDE BY SMALL COMPOUNDS 
Compounds are reported which helps in reducing the deposition of amyloids in brain either 
by inhibiting the enzymes or by inhibiting aggregates of aβ peptide by the use of antibodies, 
small peptides, or small organic molecules, increasing amyloid degradation using amyloid 
vaccines. Earlier it was found out that congo red and thioflavin T shows fluorescence when 
acted on amyloids and also showed specific interaction and inhibited them upto some 
extent[14]. Here we have shown that few small compounds can be used to inhibit the 
amyloids in vivo. Several compounds which we have found out are curcumin, resveratrol, 
indomethacin, atorvastatin, simvastatin.  
Curcumin:  the phenolic yellow curry pigment has anti-inflammatory and anti oxidative 
activities and can also stop oxidative damage and cognitive impairments. It also acts as a 
promising inhibitor for amyloid aggregation. It has been found out that it particularly binds to 
the aβ binding site and also prevents toxicity and oligomer formation. In mice models when 
curcumin was used, preferential labelling of amyloid plaques was seen. In vivo studies say 
that curcumin injected into aged Tg mice crossed the blood brain barrier and also bound to 
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amyloid plaques. Hence it acts as a both as a blocking agent for aggregation and also stops 
fibril formation both invivo and invitro [15]. 
Atorvastatin: It belongs to the statin group. It has been found out that high cholesterol level 
in body can enhance the risk of development of Alzheimer’s disease. Cholesterol metabolism 
and catabolism are seen to be affected by neurodegenerative disease. Literature say that APP 
and aβ production depend on cholesterol content and on isoprenoid intermediates in 
cholesterol biosynthesis pathway. Hence, reducing the cholesterol content may decrease the 
aβ formation. So this was found as evidence suggesting that inhibitors of cholesterol 
synthesis like statins could have a therapeutic role in AD and may inhibit the aggregation of 
abeta peptide [17]. 
Phenothiazines: Phenothiazines such as azure A and azure B have been shown to act as 
cholinesterase inhibitor when combined with rivastignine. They have been shown to slow 
down the process of aggregation of AD [18].  
CHEMBL: It is a database of bioactive drug like molecule. It contains 2D structures and also 
calculated properties. It was used for drug discovery research problems. It contains 5.4 
million bioactivity measurements for 1 million compounds and 5200 protein targets [19]. The 
access is available through web services at http://www.ebi.ac.uk/chembldb   
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3. MATERIALS AND METHODS: 
 
3.1 Tools and bioinformatics softwares used 
3.1.1    Pubchem(pubchem.ncbi.nlm.nih.gov) 
3.1.2    NCBI 
3.1.3    Swissmodel.expacy.org 
3.1.4    Pubmed 
3.1.5    Chemical entities of biological interest(chebi) 
3.1.6    PDB (pdb.org) 
3.1.7    Tango  
3.1.8    Waltz 
3.1.9    Fold amyloid 
3.1.10 Open babel software 2.3.1 
3.1.11 Rasmol 
3.1.12 Hex 6.3 
3.1.13 Swissdock 
3.1.14 Swisspdb viewer  
3.1.15 ligplot+ 1.3.6 and dimplot 
 
3.2 Protocol followed 
3.2.1 Interaction between two proteins: i.e protein –protein interaction 
            Retrieval of amino acid sequence of 1IYT protein from NCBI 
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           3-D structure of the protein model was retrieved from PDB (protein data bank) 
  
 
            3-D structures of the small compounds was retrieved from Pubchem 
 
 
             Energy minimisation of the 3-D structures of protein was done by chimera 
 
 
                Docking of protein protein complex was done by hex 6.3 
 
 
           Retrieval of the 2-D structure of the protein protein complex by liplot+  
3.2.2 Inhibition of amyloid beta peptide(1IYT) 
             Retrieval of 3-D structure of 1IYT from PDB (protein data bank) 
 
 
             Collection of small ligand compounds from Pubchem database 
 
 
             Conversion of all the ligand 3-D compounds from .sd file format to .mol2 file format 
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          Docking of all the ligands compounds with the amyloid beta peptide by swissdock 
 
 
              Analysis of binding energy and site of binding obtained from docking by chimera 
 
 
                  Saving of the output from chimera in.pdb file format 
                         
 
                        Energy minimisation of the result in swisspdb viewer 
 
 
                                           Analysis of 2D structure using ligplot+    
 
3.3 METHODOLOGY 
3.3.1 Retrieval of amino acid sequence of 1IYT protein from NCBI and PDB 
NCBI stands for National Center for Biotechnology Information. It is a part of United States 
National Library of Medicine (NLM) and is a branch of National Institutes of Health (NIH). 
NCBI contains databases which are used in biotechnology and biomedicine. Major databases 
include GenBank for DNA sequences and PubMed . NCBI contains databases by the help of 
which we can examine and research on the structure and function of biologically important 
molecules. It can provide us with information about molecular biology, biochemistry and also 
genetics. Such databases are of great use in the field of research in biotechnology and 
biomedicine. URL is http://www.ncbi.nlm.nih.gov. PDB (protein data bank) provides us with 
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the 3-dimentional structural data of macromolecules such as proteins and nucleic acids. This 
was founded in Brookhaven National Laboratories (BNL). This is of much importance 
because the understanding of the structure of the compounds is the basic step.  
a) The above URL was used for retrieval of amino acid sequence 
b) From there, the PDB link was used or else directly http://www.rcsb.org was used 
c)  The amyloid beta peptide with the PDB ID 1IYT was selected 
d) The FASTA sequence and the PDB file was downloaded. 
 
Figure (4): Homepage of PDB database from where the abeta peptide (PDB ID: 
1IYT) was downloaded. 
 
Figure5: 3D structure of 1IYT in rasmol(left) and rasmol command line (right)    
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3.3.1 Energy minimization of protein by chimera 1.6.1 
Chimera 1.6.1 is used for visualizing or analyzing molecular structure and data which 
is related to it. The docking results can be visualized using this extensible programme. 
It speciality is that it can minimise energy of molecules providing them with high 
stability.  
a) Chimera was opened and the structure of the amyloid beta peptide was retrieved. 
b) Total residues were selected. 
c) The tool option was selected. Then structure editing option was used and 
minimized structure option was clicked. 
d) The minimized structure was saved in .pdb format for further use. 
3.3.2 Prediction of the amyloidogenic region using various softwares. 
Prediction of the amyloidic region in the polypeptide chains is very important because such 
regions are responsible for amyloid formation and aggregation. These softwares are useful to 
predict positions of amyloidogenic regions in protein chains. 
a) Tango software 
It is also a computer algorithm to predict aggregation nucleating regions in proteins as 
well as the effect of mutations and environmental conditions on the aggregation 
propensity of these regions. Tango correctly predicts the aggregation propensities of 
several disease related mutations in the Alzheimer’s b-peptide. The server is available 
at http://tango.crg.es/protected/correctlogin.jsp using this URL, the protein sequence 
in FASTA format was submitted and the result was generated automatically. Here we 
got the amyloidogenic region between 16-21 and 32-36.  
b) Waltz software 
Waltz was developed with the main aim of prediction of amyloidogenic region. With 
the help of waltz scientists have been able to find out new unknown amyloid 
aggregates. The prediction of amyloid aggregates is the main starting point for 
research related to amyloid formation. The server is available at 
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http://waltzswitchlab.org. Here again the protein FASTA sequence was submitted 
online and the result was generated after sometime.  
 
  FIGURE 6: waltz page where input of the protein sequence is given in FASTA    
format. 
 
 
                 Figure 7: waltz prediction of the amyloidogenic region. 
 
  
Again this software also gave us the same result. The amyloidic region is between 16-
21 and 32-36. 
c) Fold amyloid software 
Here we take the pdbid of the abeta 42 peptide and copy and paste the sequence in the 
space provided. Here as well we use the fasta format. The result is generated 
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automatically the url for the website is http://antares.protres.ru/fold-amyloid/. Here 
also we get the same result i.e the amyloidic region between 16-21 and 32-36.   
 
Figure 8: fold amyloid server where the input is given in the FASTA format. 
 
 
       Figure 9: tango result of amyloidogenic region prediction. 
 
 
 
 
27 | P a g e  
 
3.3.3 Docking by Hex 6.3 
Hex 6.3 is a molecular graphics program developed by Dave Ritchie. It is used for 
docking of protein with ligands and also docking between two proteins can also be 
done. It is mainly used for calculating intermolecular “energies”. Energy is mainly 
related to all interactions between the molecules in terms of van der waal’s, 
electrostatic.  
a) Hex 6.3 was opened, then from the file the abeta peptide was input as the receptor 
and the same peptide was input as the ligand.  
b) The option control was clicked and docking was selected and activated. 
c) The docking result was obtained after 3 
d)  The binding energy(delta E)  after the docking was complete was saved. 
e) The docking complex was saved in .pdb format for future use. 
 
Figure 10: peptide peptide docking complex. 
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3.3.4  Inhibition of amyloid beta peptide by small compounds. 
The already minimized protein structure was selected as the target for the 
inhibition study of it by various small compounds.  
 
3.3.5  Retrieval of small compounds from pubchem 
Pubchem is a database which provides us with structures of small organic 
molecules. It also contains information related to its origin and related literatures. 
It is updated by NCBI. Compounds are freely downloaded in .sd file format or 
chemical (CID) format. 
a) The url for the site is pubchem.ncbi.nlm.nih.gov. 
b) In the search box name of the inhibitors was typed. 
c) The 3-D structures was retrieved in .sd file format. 
3.3.6   Conversion of all the compounds from .sd file format to mol2 file format 
using OpenBabel software 2.3.1 
It is used for searching, converting file format and analyzing chemical 
compounds. It is also used in molecular modelling and bioinformatics.  
a)Open Babel 2.3.1 window was opened. 
b) the input format was selected as .sd file format and then 3 dimensional structure 
was sleceted and then the output format was selected as mol2 file format. 
c) the output was saved in a particular folder for future use. 
3.3.7 Docking of abeta peptide and small ligand using swissdock. 
Swissdock is a web server to predict the molecular interactions that may occur 
between a target protein and a small compound. It is based on EADock DSS 
engine , combined with setup scripts for curating common problems and for 
preparing both the target input and ligand input files[5]. The swissdock site is 
available online at http://www.swissdock.vital-it.ch . Here the structure of the 
target protein and as well as that of ligand, can be automatically prepared for 
docking. All calculations are performed on server side. The docking results or the 
docking predictions can be easily visualized in UCSF chimera molecular viewer, 
which can be downloaded directly from web server.   
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a) Firstly submit docking was clicked 
b) In the target selection the minimized aβ peptide was uploaded. 
c) Ligand selection was similarly used to upload the small molecules or 
inhibitors. 
d) The job name was also given 
e) Email address was given . 
f) The result was automatically generated after 1 to 2 hours and it was 
downloaded as .chimerax file and was viewed in chimera. 
g) The docked result was examined using chimera and the amyloidic region was 
highlighted and the least delta G value checked. The site of binding of the 
ligand in the protein was also studied. 
h) The result was saved in .pdb file format 
3.3.7  Ligplot/dimplot analyses to interprete the residues and bonds involved in 
binding at the binding site 
a) ligplot window was opened 
b) the protein ligand complex was opened in .pdb file 
c) the ligplot analysis was done and for protein protein interaction dimplot 
analysis was done. 
d) the figure was saved. 
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Alzheimer’s disease (AD) pathogenesis is widely believed to be driven by the production and 
deposition of the amyloid beta peptide(Aβ) [6].In the current study mechanism of inhibition 
of  the small compounds on the target protein was studied. Attempt was made to study the 
potential binding sites between amyloid inhibitor compounds and aβ peptide. Till now no 
such drugs are approved that can the formation of amyloid deposit. Hence in silico approach 
was used to study the mechanism of binding between them. Abeta is a short peptide with 42 
residues. It consists of two alpha helical regions. Main characteristics of the amyloids are it 
has a cross beta structure irrespective of the source of protein, it is highly ordered , it 
aggregates very easily and is stable and can’t be reversed. It also shows binding to specific 
dyes like congo red and thioflavin –T. The fold amyloid server successfully predicted the 
amyloidogenic region in the peptide. Amino acid portin from16-21 and (GYEVH) and 32-36( 
VFFAEDVGSN) were found to be amyloidogenic as shown in fig(11 ). 
                                 
Figure 11: solution structure of amyloid beta peptide (1-42) with pdb id :1IYT. The 
amyloidogenic region ( 16-21 and 32-36) is highlighted in green colour.   
Inhibitory compounds were selected which were already reported to inhibit the amyloid 
protein in vivo. The compounds selected were curcumin, atorvastatin, azure A, azure B, 
epigallocatechin gallate, CHEMBL205907, CHEMBL208350, CHEMBL208504, 
CHEMBL236182, CHEMBL236187, CHEMBL 236189, CHEMBL236192, indomethacin, 
vitamin e. 
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To identify the binding sites between aβ peptide and the compounds molecular docking was 
done using swissdock. Figure(12-left) shows the docking result between aβ peptide and 
curcumin. It was observed that the ligand binds in the vicinity of the amyloidogenic region 
VFFAEDVGSN formed by  32-36 residues. Later ligplus software was used to identify the 
interaction between the both which showed a special hydrophobic interaction in fig(12-right). 
The peptide residues which were involved in hydrophobic interaction were Ala21, glu22, 
Gly25,Lys28, Val24, Phe20.  
This suggests that inhibitor binds near the amyloidogenic region and prevents 
aggregation by masking the amyloidogenic region.  
 
Figure 12: docking complex of abeta peptide with curcumin using swissdock(left) 
Corresponding Ligplot image (right) of the docking complex showing specific 
interactions. 
 
Figure (13 ) shows the docking result between the abeta peptide and atorvastatin. Here 
the ligand was found to interact with the 32-36 amyloidogenic region composed of 
VFFAEDVGSN . Ligplus  shows the peptide residue which were involved in 
hydrogen bonding and also hydrophobic interaction. The residue involved in 
hydrogen bonding was Lys16 and the residues involved in hydrophobic interaction 
were Leu17, Ala21, Gly25, Val24, Leu34, Phe20. 
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Figure 13: docking complex of abeta peptide with atorvastatin using 
swissdock(above).Corresponding Ligplot image (below) of the docking complex 
showing specific interactions.   
 
Figure (14 ) shows the docking result between aβ peptide and azure A. Here the 
compound was found to bind in the vicinity of the amyloidogenic 32-36 region. 
Ligplus showed the hydrophobic interaction .The major residues involved were 
Phe20, Leu17, Ala21. 
 
  
 b 
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Figure 14: docking complex of abeta peptide with azure A using swissdock(left) 
Corresponding Ligplot image (right) of the docking complex showing specific 
interactions.   
 
 
Figure (15 ) shows the docking result between aβ peptide and azure B. Here again the 
compound was found to bind in the vicinity of the amyloidogenic 32-36 region. 
ligplus showed the major residues Ala2,Glu22,Ser26,Gly25,Val24 involved in 
hydrophobic interaction.  
  
Figure 15: docking complex of abeta peptide with azure B using swissdock(left) 
Corresponding Ligplot image (right) of the docking complex showing specific 
interactions.  
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Fig(16 ) shows the docking result between abeta peptide and epigallocatechin gallate. 
The compound was shown to inhibit in the amyloidogenic region 32-36. Ligplus 
showed hydrophobic interactions between the Glu22,Gly25,Ala21,Vall8 residues of 
the peptide and the atoms of the inhibitor molecuole. 
 
 
 
 
 
 
 
 
 
 
 
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Docking complex of abeta peptide with epigallocatechin gallate using 
swissdock(left).Corresponding Ligplot image (right) of the docking complex showing 
specific interactions.  
 
Fig(17 ) shows the docking result between abeta peptide and CHEMBL205907. Here 
also the ligand bound to the amyloidogenic region highlighted in red colour. The 
ligplot showed hydrogen bonding between the Asp23,Glu22, Ser21 residues of the 
peptide and the ligand and hydrophobic interaction between the Asn27 residue of 
peptide with the ligand. 
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Figure 17: docking complex of abeta peptide with CHEMBL205907  using 
swissdock(left).Corresponding Ligplot image (right) of the docking complex showing 
specific interactions. 
  
 
 
Fig(18) shows the docking result between abeta peptide and CHEMBL208350. The 
ligand binds near amyloidogenic region. Ligplot showed hydrophobic interaction 
mainly involving the residues Ala21, Lys28, Leu34, Phe20, Val24, Met35 of the 
peptide .  
  
Figure 18: docking complex of abeta peptide with CHEMBL208350 using 
swissdock(left).Corresponding Ligplot image (right) of the docking complex showing 
specific interactions. 
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Fig (19) shows docking result between abeta peptide and CHEMBL208504. Here also 
the ligand binds near peptide sequence of 32-36 and ligplot showed hydrogen 
interaction between Leu17 and hydrophobic interaction between Ala21, Leu34, Phe20 
residues and the ligand. 
  
Figure 19: docking complex of abeta peptide with CHEMBL208504 using 
swissdock(left).Corresponding Ligplot image (right) of the docking complex showing 
specific interactions. 
 
 
Fig( 20) shows docking result between abeta peptide and CHEMBL236182. Ligplot 
shows hydrophobic interaction between Met35,Ala42, Gly38,Leu34,Val24,Phe20 
residues and ligand. 
   
Figure 20: docking complex of aβ peptide with CHEMBL236182 
swissdock(left).Corresponding Ligplot image (right) of the docking complex showing 
specific interactions. 
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Fig(21) shows docking result between aβ peptide and CHEMBL 236187.ligplot 
shows hydrophobic interaction between Val24,Leu34,Lys28,Leu17,Met35 residues 
and ligand. 
  
Figure 21: docking complex of aβ peptide with CHEMBL 236187 using 
swissdock(left).Corresponding Ligplot image (right) of the docking complex showing 
specific interactions. 
  
Figure 22: shows the docking result between aβ peptide and CHEMBL236192 . The 
key residues involved in hydrophobic interaction between the both are Val24, Gly25, 
Glu22, Ala21, Met35.  
  
Figure 22: docking complex of aβ peptide with CHEMBL 236192  using 
swissdock(left).Corresponding Ligplot image (right) of the docking complex showing 
specific interactions. 
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FIG 23  shows docking result between aβ peptide and indomethacin. Ligplot shows 
hydrogen bonding between Lys28 and hydrophobic interaction between Val24, 
Gly38, Val39, Met35, Leu34 and the ligand. 
  
Figure 23: docking complex of aβ peptide with indomethacin using 
swissdock(left).Corresponding Ligplot image (right) of the docking complex showing 
specific interactions. 
  
Fig 24 shows docking result between aβ peptide and vitamin e(alpha tocopherol). 
Ligplot shows hydrophobic interaction between the residues Phe20, Leu34, Gly35, 
Ala30, Val24 and the ligand. 
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Figure 24: docking complex of aβ peptide with vitamin e(alpha tocopherol)using 
swissdock(above).Corresponding Ligplot image (below) of the docking complex 
showing specific interactions. 
  
Thus the docking result showed that all the inhibitor compounds bound near the 
vicinity of the amyloidogenic region of the aβ peptide as predicted by fold amyloid 
software.  
      Table(2): list of selected inhibitor molecule with delta G value of docking with aβ 
peptide. 
Sl.n
o 
Inhibitor name Pubchem 
id/chembl 
id 
2D structure Delta G 
value 
1. curcumin CID 
969516 
 
-7.16 
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2. Atorvastatin CID 
60823 
 
-8.09 
3. Azure A CID 
13735 
 
-8.26 
4. Azure B CID 
68275 
 
-7.09 
5. Epigallocatechi
n gallate 
CID 
65064 
 
-7.13 
6. CHEMBL 
205907 
CID11962
185  
 
-7.3 
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7. CHEMBL 
208350 
CID44410
629  
 
-7.57 
8. CHEMBL 
208504 
CID44410
506 
 
-7.41 
9. CHEMBL 
236182 
CID44435
381 
 
-8.07 
10. CHEMBL 
236187 
CID44435
387 
 
-8.36 
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11. CHEMBL 
236189 
CID44435
389 
 
-8.07 
12. CHEMBL 
236192 
CID44435
393 
 
-8.14 
13. Indomethacin CID3715 
 
-7.91 
15. Vitamin e(alpha 
tocopherol) 
CID2116 
 
-7.00 
 
Docking study was also done between two aβ peptide molecules to understand the 
mechanism of binding and type of interactions. Fig(27 ) shows the docking result of 
protein protein interaction. It has been noticed that there is a strong binding between 
the two aβ molecules which has a binding energy of -435.87 KJ/mol.  
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Figure 25: peptide peptide docking result. 
 
 
                        CONCLUSION  
In the current study we found out that the small compounds which we found out based 
on the literature reviews bound to the aβ peptide in the vicinity of the amyloidogenic 
region. Amyloid beta peptide is the main component which is responsible for the 
onset of Alzheimer’s disease. Based on the docking study between amyloid inhibitor 
small compounds and aβ peptide we gained knowledge and by the help of which we 
could prevent further aggregation. The amyloidogenic region in the aβ peptide was 
predicted by the fold amyloid software. It was found out that the inhibitor compounds 
bound in the vicinity of the amyloidogenic region suggesting their mechanism of 
action by masking the amyloidogenic region and further preventing aggregation of the 
peptide. By the use of ligplot software we could see the detailed interaction between 
the inhibitors and the peptide. It was concluded that the major interaction between 
them was due to the hydrophobic and hydrogen bonding which made the complex 
more stable which might play a role in preventing further aggregation.   
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